Contrast Media in Radiology: Types & Risks

Contrast media — more accurately called contrast agents rather than “dyes” — are a cornerstone of modern diagnostic imaging. From CT angiography to fluoroscopic gastrointestinal studies, these substances improve the conspicuity of structures or physiology that may be poorly seen without them. For radiologic technology students preparing for the ARRT exam, contrast administration, adverse reactions, emergency response, and pharmacology are relevant study topics within the published content specifications.

This guide reviews the difference between ionic and nonionic agents, common administration routes, agent-specific screening, acute reaction recognition and response, kidney risk, pregnancy/lactation, and key safety concepts relevant to technologist education. Product labeling and local protocols still govern any individual administration.

What Are Contrast Media?

Contrast media are substances administered to improve the visibility of internal structures or physiology. In CT and angiography the principal positive intravascular agents contain iodine, whose high atomic number (53) strongly attenuates X-rays. Fluoroscopic and CT gastrointestinal imaging may instead use barium sulfate, an iodinated enteric agent, or a neutral/negative agent, depending on the question and patient risks.

Think of it this way: blood vessels, organs, and adjacent soft tissues may have similar attenuation. Introducing an appropriate positive agent into the bloodstream or GI tract increases attenuation and separation from surrounding tissues. On liver CT, IV contrast can demonstrate vascular anatomy, enhancement patterns, and lesions that may be less conspicuous without it.

Iodinated contrast agents can be described by ionization (ionic vs. nonionic), osmolality (high, low, or iso-osmolar), and structure (monomer vs. dimer). These related—but not interchangeable—properties influence viscosity, tolerability, and use. They do not by themselves determine every clinical risk.

Ionic vs. Nonionic Contrast Media

Ionization is an important study concept, but it must be considered together with osmolality, molecular structure, concentration, route, and the individual product label. “Ionic” does not automatically mean “high-osmolality.”

Property	Traditional ionic monomer (HOCM)	Modern nonionic LOCM/IOCM
Dissociation in solution	Dissociates into a contrast anion and a cation (such as sodium or meglumine)	Does not dissociate — remains as a single molecule
Osmolality	High: roughly 1,400–2,100 mOsm/kg (about 5–7× plasma, formulation dependent)	LOCM: roughly 2–3× plasma; iodixanol is iso-osmolar to plasma (values depend on iodine concentration)
Iodine-to-particle ratio	1.5:1 (monomer)	3:1 (monomer) or 6:1 (dimer)
Adverse reaction rate	Historically about 5–15% for all acute adverse events	About 0.2–0.7% in large series for all acute events or allergic-like reactions, depending on definition
Severe reaction rate	Higher than with modern nonionic agents	Serious acute reactions are rare; historically about 0.04%
Common examples	Diatrizoate formulations (some remain useful for selected enteric procedures)	Iohexol (Omnipaque), Iopamidol (Isovue), Ioversol (Optiray), Iodixanol (Visipaque)
Primary uses today	Selected oral/rectal or other nonvascular uses; generally replaced for intravascular use	IV and intra-arterial injections (CT, angiography)

Why Osmolality Matters

Osmolality — the concentration of dissolved particles in solution — contributes to fluid shifts and some physiologic effects, especially with high-osmolality intravascular agents. It does not explain all acute reactions: allergic-like reactions arise through mediator-release pathways and can occur on a first exposure. Hyperosmolality can contribute to:

• Vasodilation — the patient feels a warm flush or burning sensation
• Cardiovascular effects — blood-pressure or heart-rate changes in susceptible patients
• Intravascular volume expansion — a larger fluid shift may worsen heart failure or pulmonary edema in susceptible patients
• Endothelial and red-cell effects — more prominent with older high-osmolality agents
• Dehydration of red blood cells — increased rigidity, reduced capillary flow

Modern nonionic agents produce fewer acute adverse events than ionic HOCM and have largely replaced HOCM for intravascular use. Most nonionic monomers are still hyperosmolar relative to plasma (about 290 mOsm/kg); only iso-osmolar formulations closely match plasma.

Types of Contrast Media by Route of Administration

Contrast agents are also classified by how they enter the body. Each route has specific indications, preparation requirements, and patient care considerations.

Intravenous (IV) Contrast

IV contrast is the most common route for CT and some radiographic studies (IV pyelography). It's administered through a peripheral vein, typically the antecubital fossa, using a power injector at rates of 1-5 mL/second depending on the study. IV contrast opacifies the vascular system and enhances solid organs through their blood supply. Timing is everything — arterial phase, portal venous phase, and delayed phase images each show different information.

Oral Contrast

Oral or rectal contrast can opacify the gastrointestinal tract, but its use, agent, volume, and timing are indication- and protocol-dependent; many emergency and routine CT examinations do not require positive oral contrast. Options include dilute barium sulfate, water-soluble iodinated agents, and neutral/negative agents. Barium sulfate is insoluble and is generally avoided when perforation or a postoperative leak is suspected because leakage can cause mediastinal or peritoneal complications. Water-soluble iodine is usually preferred first; if that study is negative but clinical suspicion remains, a carefully selected follow-up barium study may detect a small leak. Hyperosmolar diatrizoate can cause dangerous pulmonary edema if aspirated, so aspiration risk also affects agent choice.

Intrathecal Contrast

Intrathecal iodinated contrast is used for myelography and CT cisternography. Only a nonionic agent and concentration specifically labeled for intrathecal use—such as appropriate iohexol or iopamidol formulations—may be used. Iodixanol (Visipaque) is contraindicated intrathecally; accidentally giving an intravascular-only product by this route can cause seizures, cerebral edema, coma, or death. Administration and post-procedure positioning, observation, medication review, and hydration follow the product label and institutional protocol rather than a universal bed-rest rule.

Intra-Articular Contrast

Direct arthrography introduces dilute contrast into a joint under image guidance. Iodinated contrast is used for fluoroscopy/CT arthrography; dilute gadolinium-based contrast is commonly used for MR arthrography, generally as an off-label intra-articular use in the United States. Agent, dilution, and aseptic technique must follow the supervising service's protocol.

Patient Screening Before Contrast Administration

Before a contrast procedure, screen for risks relevant to the chosen agent and route and follow the current product label and institutional policy. The goal is not to produce a generic “cleared/not cleared” checklist; it is to identify risks that change agent selection, preparation, monitoring, or the risk-benefit decision.

Essential Screening Questions

• Previous reaction to the same contrast class? — Record the agent, route, timing, symptoms, severity, and treatment. This is the strongest predictor of another allergic-like reaction. An unrelated allergy or a reaction to a different class is not the same risk
• Asthma or other allergies? — Asthma and unrelated allergies modestly increase allergic-like reaction risk, but ACR does not recommend withholding contrast or premedicating solely for shellfish, povidone-iodine, food/drug allergies, seasonal allergies, or asthma
• Kidney disease or AKI? — For IV iodinated contrast, stable eGFR ≥30 mL/min/1.73 m² has little evidence of independent nephrotoxic risk. AKI or eGFR <30 prompts individualized risk-benefit review and prophylaxis when appropriate; it is a relative, not absolute, contraindication
• Metformin use? — Metformin neither causes post-contrast AKI nor increases its incidence. Under ACR guidance, continue it for IV iodinated contrast when there is no AKI and eGFR is ≥30. With AKI, eGFR <30, or an arterial catheter study that could embolize the renal arteries, stop at/before the procedure, withhold 48 hours, and restart only after renal function is re-evaluated and stable. Follow local policy because FDA labeling is more restrictive
• Pregnancy or lactation? — Iodinated contrast crosses the placenta but should not be withheld when needed diagnostically. GBCAs should not be routine in pregnancy and are reserved for important benefit that outweighs uncertain fetal risk. Breastfeeding need not be interrupted after maternal iodinated contrast or a GBCA
• Thyroid circumstances? — Iodinated contrast can rarely precipitate thyrotoxicosis; avoid it in acute thyroid storm when possible. A history of hyperthyroidism alone is not a reason to restrict contrast. Iodine also interferes temporarily with planned radioactive-iodine uptake, imaging, or therapy
• Other agent-specific risks? — Ask about suspected GI perforation or aspiration risk for enteric contrast and previous hypersensitivity to the selected ultrasound agent or its components. Multiple myeloma alone is not a supported independent risk factor for post-contrast AKI

The Premedication Protocol

A prior severe allergic-like reaction to the same class is a relative contraindication. Consider an alternative examination, a different agent within the class, and—when appropriate—premedication. Premedication is imperfect, may delay diagnosis, and is not recommended solely for unrelated allergies or a reaction to another contrast class. When elective premedication is selected, ACR options include:

• Prednisone 50 mg PO — at 13, 7, and 1 hour before contrast, plus diphenhydramine 50 mg IV, IM, or PO 1 hour before. The diphenhydramine component is historical and optional
• Or methylprednisolone 32 mg PO — at 12 and 2 hours before contrast; diphenhydramine may be added
• Accelerated IV option — methylprednisolone sodium succinate 40 mg IV (or hydrocortisone 200 mg IV) immediately and every 4 hours until contrast, plus diphenhydramine 50 mg IV 1 hour before; this normally takes 4–5 hours

Regimens lasting less than 4–5 hours have no evidence of efficacy. In a true emergency, urgency may outweigh prophylaxis; if contrast is given, ensure appropriate monitoring and personnel/equipment able to treat a breakthrough reaction. Premedication never substitutes for readiness.

Contrast Media Adverse Reactions: Recognition and Management

Acute adverse events range from mild to life-threatening. ACR classifies them both by type (allergic-like versus physiologic) and by severity (mild, moderate, or severe). This distinction matters: warmth and limited nausea are physiologic, whereas urticaria, bronchospasm, and laryngeal edema are allergic-like. Vasovagal bradycardia/hypotension and anaphylaxis require different treatment.

Management by Severity

Severity	Symptoms	Immediate Action	Medications
Mild	Limited hives/itching; limited nausea/vomiting; warmth or flushing	Stop injection if ongoing; assess appearance, speech/voice, breathing, pulse, blood pressure, and oxygenation; preserve IV access and observe.	Often none. For symptomatic hives, consider an antihistamine (for example diphenhydramine 25–50 mg PO, or IM/IV for more extensive symptoms) under protocol.
Moderate	Diffuse hives; throat tightness/hoarseness without dyspnea; mild/moderate bronchospasm; protracted vomiting; symptomatic vasovagal reaction	Call the supervising clinician/response team, monitor continuously, preserve IV access, support airway/breathing, and give oxygen as indicated. Treatment is symptom-specific.	Bronchospasm: albuterol 2 puffs, repeat as protocol permits; add epinephrine 0.3 mg IM (1 mg/mL) for moderate/progressive allergic-like symptoms. Give IV isotonic fluid for hypotension; atropine is for persistent symptomatic bradycardic vasovagal hypotension.
Severe	Laryngeal/facial edema with dyspnea, severe hypoxic bronchospasm, anaphylactic shock, severe hypotension, pulmonary edema, seizure, or arrest	Activate emergency response/911 immediately; support airway and oxygenation, monitor, preserve IV access, and give rapid isotonic fluid for hypotension. Start CPR/AED only if unresponsive and pulseless.	For anaphylaxis without arrest: epinephrine 0.3 mg IM (1 mg/mL), repeat every 5–15 min as needed; trained clinicians may use carefully titrated epinephrine 0.1 mg IV (0.1 mg/mL) for severe/persistent hypotension. The 1 mg IV dose is reserved for cardiac arrest under ACLS, not routine anaphylaxis.

Post-Contrast AKI and Contrast-Induced AKI

The older term “contrast-induced nephropathy (CIN)” encouraged causal attribution whenever creatinine rose after contrast. Current ACR–NKF terminology separates contrast-associated acute kidney injury (CA-AKI)—AKI occurring soon after contrast, whether or not contrast caused it—from contrast-induced acute kidney injury (CI-AKI), the subset actually caused by contrast. AKI is generally diagnosed using contemporary KDIGO serum-creatinine/urine-output criteria, not the obsolete stand-alone “25% or 0.5 mg/dL” CIN definition. Controlled studies show that the nephrotoxic risk of modern IV iodinated contrast was historically overstated.

Practical risk assessment:

• Greatest established risk: active AKI or severe CKD. Stable eGFR <30 mL/min/1.73 m² is the evidence-supported threshold most often used for heightened CI-AKI concern
• Stable eGFR 30–44: IV iodinated contrast is either not nephrotoxic or only rarely so; prophylaxis may be considered individually when there are high-risk circumstances such as recent AKI or multiple risk factors
• Stable eGFR ≥45: IV iodinated contrast is not an independent nephrotoxic risk factor in available controlled studies
• Other proposed factors: dehydration, diabetes, cardiovascular disease, diuretics, advanced age, hypertension, and closely spaced doses may accompany CA-AKI risk, but many have not been rigorously confirmed as independent CI-AKI risks. Multiple myeloma alone is not supported as one

Prevention: For patients with AKI or eGFR <30 who are not on maintenance dialysis, ACR recommends IV volume expansion with isotonic fluid when not contraindicated by heart failure or another hypervolemic condition. The ideal regimen is unknown; typical protocols begin about 1 hour before and continue 3–12 hours after (for example, fixed 500 mL before/after or 1–3 mL/kg/hour). Prophylaxis is not routinely indicated for stable eGFR ≥30 or chronic dialysis. Do not reduce the contrast dose below a diagnostic threshold; there is no established IV renal-safety advantage of iodixanol over modern LOCM. Withhold nephrotoxic medications only after individualized clinical review—not as a blanket technologist instruction. Metformin management follows the separate rules above; it is held to prevent accumulation if AKI occurs, not because metformin is nephrotoxic.

Contrast Media Safety: Essential Protocols

Power Injector Safety

Core safety practices for power injection include:

• Verify IV patency — assess the site and flush by hand with saline according to protocol; pain, swelling, abnormal resistance, or other evidence of poor access must be resolved before power injection
• Avoid air embolism — carefully purge all air from the IV tubing before connecting to the patient
• Match flow and pressure to the access device — a 20G or larger catheter is generally preferable at ≥3 mL/s, although a well-positioned 22G may tolerate up to 5 mL/s. Use only power-rated central/PICC access and stay within manufacturer limits
• Monitor the injection site when feasible and tell the patient to report pain or swelling immediately — extravasation can rarely cause blistering, tissue necrosis, or compartment syndrome
• Know the extravasation protocol — stop injection, preserve access initially, and have a clinician examine tenderness, swelling, erythema, perfusion, sensation, and active/passive motion. Elevate the limb; cold or warm compresses may be used, but neither has proven superiority and no routine drug treatment is established

Most extravasations resolve without complication. Discharge only after appropriate evaluation and provide explicit return precautions for worsening pain/swelling, paresthesia, reduced motion, poor perfusion, blistering, or ulceration. Obtain urgent surgical consultation for clinical concern about compartment syndrome or severe injury; do not use extravasated volume alone as the trigger. Document the event, estimated volume, examination, care, instructions, and required notifications.

Contrast Media Storage and Handling

Store each product exactly as its prescribing information specifies; many iodinated agents are kept at controlled room temperature and protected from light. Approved warming to about body temperature lowers viscosity, but routine warming is not required for every injection. Use a validated warmer and never microwave a container. Treat single-dose containers as single-patient products and discard unused contents; handle multi-dose containers according to the manufacturer, pharmacy/infection-control policy, and applicable standards—there is no universal CDC rule that every opened multi-dose contrast vial expires at 24 hours.

Documentation

Document the agent name, dose/volume, route, and required administrator details in the patient record; record lot number when required by policy or regulation. For an adverse event, record onset, specific symptoms/signs and severity, vital signs, treatment and response, disposition, and the exact agent rather than only “contrast allergy.”

Contrast Media for Magnetic Resonance Imaging (MRI)

MRI contrast agents are fundamentally different from iodinated contrast. Most use gadolinium bound tightly to a chelate; the paramagnetic complex commonly shortens T1 relaxation and increases signal on T1-weighted images. GBCAs can be linear or macrocyclic and ionic or nonionic, but clinical NSF decisions should use the ACR agent groups rather than structure alone:

• Group I (gadodiamide, gadopentetate dimeglumine, gadoversetamide) — greatest number of NSF associations; avoid in at-risk patients and FDA labeling contraindicates these agents in that setting
• Group II — agents associated with few, if any, unconfounded NSF cases; examples include macrocyclic gadobutrol, gadoteric acid/gadoterate, and gadoteridol, but also linear gadobenate dimeglumine and gadoxetate. Structure is therefore not a perfect substitute for ACR group
• Group II* provisional — newer agents such as gadopiclenol may be managed like group II or group III according to local practice while real-world high-risk data mature

Nephrogenic systemic fibrosis (NSF) is a severe, sometimes fatal fibrosing disease linked mainly to GBCA exposure in patients with AKI, dialysis, or stage 4–5 CKD. Gadolinium is not categorically contraindicated at eGFR <30. At a standard dose, ACR considers the NSF risk from a group II GBCA sufficiently low that renal-function assessment is optional before IV administration, and group II is strongly preferred when a patient is at risk. Use the lowest diagnostic dose. Group I agents carry the major historic risk (estimated 1–7% after one or more exposures in severe/end-stage CKD) and should not be used in at-risk patients.

All GBCAs can leave trace gadolinium in the body; retention is generally greater with linear than macrocyclic agents. FDA requires class warnings and a Medication Guide. No adverse health effect from brain retention has been established, but use should still be justified and the agent and dose recorded, particularly for patients likely to receive many enhanced MR examinations.

Pregnancy and Breastfeeding

Iodinated contrast and GBCAs cross the placenta. ACR does not recommend withholding iodinated contrast in pregnancy when it is needed for diagnosis; no documented neonatal hypothyroidism has followed maternal intravascular water-soluble iodinated contrast, and routine newborn screening is generally sufficient. By contrast, routine GBCA administration should be avoided during pregnancy. Give a low-NSF-risk GBCA at the lowest diagnostic dose only when important information cannot reasonably be obtained otherwise, will affect care during pregnancy, and the benefit outweighs uncertain fetal risk, with documented multidisciplinary review and informed consent.

Breastfeeding does not need to be interrupted after maternal intravascular iodinated contrast or a GBCA. The estimated systemic infant dose is under 0.01% of the maternal iodinated dose and under 0.0004% of the maternal GBCA dose. After informed discussion, a parent who remains concerned may choose to express and discard milk for 12–24 hours, but this is optional and stopping beyond 24 hours has little value.

Ultrasound Contrast Media

Ultrasound contrast agents are gas-filled microbubbles or microspheres that remain primarily within the blood pool, enhance backscatter, and are eliminated mainly through the lungs—not the kidneys. In the United States, Definity (perflutren lipid microspheres), Lumason (sulfur hexafluoride lipid-type A microspheres), and Optison (perflutren protein-type A microspheres) are FDA approved for selected echocardiographic indications. Lumason also has approved adult/pediatric liver and pediatric vesicoureteral-reflux indications; many other abdominal and vascular applications are off-label.

These agents have no known renal toxicity at approved doses and do not carry NSF risk. Severe reactions are rare (about 0.01% in a large Definity/Optison series), but serious cardiopulmonary and hypersensitivity reactions can occur, usually within 30 minutes. Screen for prior hypersensitivity to the selected agent or components; lipid agents Definity and Lumason contain polyethylene glycol (PEG), which matters in patients with known/suspected PEG hypersensitivity. They are contraindicated for intra-arterial injection. Have trained personnel and resuscitation equipment readily available, and use caution in unstable cardiopulmonary conditions. A cardiac shunt is no longer a blanket FDA contraindication.

How Contrast Media Relates to Patient Care

Contrast administration requires careful patient care from start to finish: confirm authorization and screening, explain expected transient sensations (such as warmth or metallic taste with iodinated contrast), verify access and dose, monitor the patient, recognize allergic-like and physiologic reactions early, and act within training, scope, and institutional policy.

For general radiography, contrast is used in studies such as voiding cystourethrography (VCUG), fistulography, sialography, and the now less common intravenous pyelogram. For CT, IV contrast is essential for many vascular, oncologic, inflammatory, and trauma indications, while many other examinations are appropriately performed without it; use is driven by the clinical question, not a rule that nearly all body CT requires contrast. Understanding arterial, portal venous, and delayed timing and bolus tracking is central to protocol performance.

Summary

Contrast media knowledge is essential for both clinical practice and the ARRT registry exam. Here's what to remember:

• Ionic vs. nonionic — Ionization and osmolality are distinct. Modern routine intravascular iodine is predominantly nonionic LOCM; iodixanol is nonionic IOCM, and ioxaglate is an ionic LOCM exception
• Screen specifically — prioritize prior reaction to the same class and ask only agent/route-relevant kidney, medication, pregnancy, thyroid, enteric, and ultrasound questions; do not require renal labs for every low-risk patient
• Classify reactions — allergic-like versus physiologic and mild/moderate/severe; many mild events need observation and reassurance rather than medication
• Treat anaphylaxis safely — adult epinephrine 0.3 mg IM (1 mg/mL), repeat per response/protocol; 1 mg IV is a cardiac-arrest dose, not an anaphylactic-shock dose
• Kidney risk — distinguish CA-AKI from proven CI-AKI. AKI or eGFR <30 warrants individualized review and usually isotonic IV prophylaxis when appropriate; stable eGFR ≥30 does not routinely require prophylaxis
• Metformin — under ACR guidance, continue for IV iodine if there is no AKI and eGFR ≥30; hold at/before contrast and for 48 hours with AKI, eGFR <30, or selected renal-embolizing arterial catheter studies, then reassess
• Gadolinium — group II GBCAs have very low NSF risk even in advanced kidney disease; avoid routine GBCA use in pregnancy. Breastfeeding can continue after iodinated contrast or GBCA
• Ultrasound contrast — microbubbles are not nephrotoxic, but rare hypersensitivity/cardiopulmonary reactions require screening and emergency readiness

For more radiography study resources, explore the X-Ray modality page, the CT Scan page, and our Patient Care in Radiography article. Visit the articles index for more exam prep and positioning guides.

Authoritative Sources

• ACR Manual on Contrast Media (2026) — primary reference for screening, fasting, warming, acute reactions, kidney risk, metformin, GI agents, GBCA/NSF, ultrasound agents, pregnancy/lactation, and extravasation
• ACR–NKF Consensus: IV Iodinated Contrast in Patients With Kidney Disease
• ACR–NKF Consensus: IV Gadolinium-Based Contrast in Patients With Kidney Disease
• FDA iohexol (Omnipaque) prescribing information — route- and concentration-specific intrathecal labeling
• FDA iodixanol (Visipaque) prescribing information — intrathecal contraindication
• FDA metformin-containing product labeling — the FDA's more restrictive iodinated-contrast instructions
• FDA Lumason prescribing information — ultrasound-contrast indications and serious reaction warning
• FDA gadobutrol (Gadavist) prescribing information and Medication Guide — class retention warning
• ACOG Committee Opinion 723: Diagnostic Imaging During Pregnancy and Lactation
• Updated ESUR Contrast Media Safety Committee extravasation guideline
• ARRT Examination Content Specifications